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Abstract
Dendritic cells (DCs) are specialized antigen-presenting cells that control T cell responses. DCs play a dual role
in inducing and orchestrating adaptive immune responses upon infection but also maintaining T cell tolerance. The
superior capacity of DCs to control immunogenicity has initiated the development of DC-targeted vaccines that aim
at inducing potent, durable and adjustable immune responses that could be clinically favourable in various human
disorders. Specific delivery of antigen to DCs has been assayed in a research setting for a couple of decades and
these efforts have now enabled implementation of DC-targeted vaccines in a clinical setting. The present review
discusses targeting of DCs with special focus on antibody-mediated delivery of antigen.
Keywords: Dendritic cells; C-type lectins; Targeting; Immune
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Dendritic cells
DC functions
Dendritic cells (DCs) are a heterogeneous group of antigen-
presenting cells (APCs) specialized in picking up, processing and
presenting antigens (Ags) to T cells [1-3]. Although these cells share
many common features, multiple different subsets with distinct
phenotype, localization and role in controlling the type of immune
response have been identified [3]. DCs are found in most tissues
including skin and mucosal surfaces, which are the most common sites
of entry for microbial pathogens, but also in secondary lymphoid
organs, in which adaptive immune responses to such pathogens are
initiated [4]. The different DC subsets express distinct pattern
recognition receptors (PRRs), e.g. C-type lectin receptors (CLRs), Toll-
like receptors (TLRs), nucleotide-binding oligomerization domain
(NOD)-like receptors, and retinoic acid inducible gene-I (RIG-I)-like
receptors [5,6]. Ligands for these receptors include pathogenic
structures, also known as pathogen-associated molecular patterns
(PAMPs) that enable detection of pathogenic (non-self) molecules.
Furthermore, PRRs recognize non-infectious structures of endogenous
origin that derive from tissue destruction and cell death - the damage-
associated molecular patterns (DAMPs) [5,7]. Receptor activation
initiate intracellular signalling that triggers different cellular responses
including internalization of Ags, production of cytokines and
chemokines followed by induction of adaptive immunity [5,8].
The interaction of DCs with T cells can lead to either different forms
of immune responses or to T cell tolerance, depending on both the
maturation state and the environmental signals received by the DCs
[6,8,9]. In the steady state, immature, migratory DCs act as sentinels in
peripheral tissues, continuously sampling the environment for Ags.
Upon encounter with antigenic structures, these cells may undergo
maturation transforming the immature DCs, having weak T cell
stimulatory capacity, into potent T cell stimulating mature DCs
[6,10,11]. The maturation process involves redistribution of major
histocompatibility complex (MHC) molecules from intracellular
endocytic compartments to the cell surface, decrease in Ag
internalization and upregulation of the surface expression of co-
stimulatory molecules required for T cell activation [6,8,12]. In
addition, DC maturation results in a switch in chemokine receptor
expression with down-regulation of receptors for inflammatory
chemokines and up-regulation of receptors for chemokines produced
in secondary lymphoid tissues, which facilitate the migration of DCs
from peripheral tissues to these tissues. Immature DCs express a
unique repertoire of inflammatory chemokine receptors, e.g CCR1,
CCR2, CCR5 and CCR6, that bind to chemokines such as CCL2, CCL5
and CCL20 allowing their access into peripheral tissues [13–15]. When
DC mature, many of these chemokine receptors are down-regulated
while other receptors are up-regulated, e.g. CCR7 [12,16]. CCR7
recognizes two chemokines, CCL19 and CCL21, which mediates entry
of DCs into secondary lymphoid tissues. CCL21 is expressed by
endothelial cells of high endothelial venules (HEV) and of lymphatic
vessels but also by stromal cells present in the T cell zone of secondary
lymphoid tissues [16]. CCL19 is produced by stromal cells and mature
DCs in the T cell zone [17]. Besides attracting maturing DCs to
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lymphoid tissues, CCL19 and CCL21 also promote extravasation of
CCR7+ naïve and memory T cells through HEV thereby orchestrating
the encounter of DCs and T cells in the T cell zone of lymph nodes
[18]. Arriving in the secondary lymphoid tissues, Ag-bearing DCs
efficiently trigger an immune response by T cells that recognize one of
the antigenic peptides presented in complex with a MHC molecule on
the DC surface membrane [17]. Migration to the lymph nodes also
occurs in the steady state, although at lower rates [16]. In this case,
antigenic peptides are presented on immature DCs and engagement
with a T cell receptor, recognizing the peptide-MHC complex, will in
most cases lead to T cell tolerance by induction of unresponsiveness in
the T cells, induction of T cell apoptosis, or by generation of regulatory
T cells (Tregs) [6,9]. Interestingly, studies have shown that in order for
steady state DCs to remain in the immature and tolerogenic state, the
suppressive activity of Tregs is required. The ability of DCs to present
Ags in a tolerogenic manner constitute a mechanism by which
peripheral tolerance complements central tolerance as a means of
controlling autoreactive T cells [6].
Antigen presentation by DCs
APCs usually present exogenous Ags on MHC II molecules and
activate CD4+ T helper cells, while Ags that are generated
intracellularly, like cytosolic Ags of viral origin, usually are presented
on MHC I molecules and activate CD8+ cytotoxic T cells [19,20].
However, DCs have the capacity to present exogenous Ags on MHC I
as well as on MHC II molecules [21].
Upon internalization of Ags from the plasma membrane, Ag is
located in vesicular compartments named early endosomes (EE),
characterized by a neutral ph. Endosomal maturation causes fusion of
EE with late compartments resulting in late endosomes (LE) displaying
lower pH than EE. Further acidification of LE is mediated by fusion
with lysosomes containing proteases and hydrolases with low pH
optima which can degrade the luminal contents into small peptides for
presentation on the MHC II molecules [22,23]. Newly synthesized
MHC II molecules assemble (α and β chains) in the endoplasmic
reticulum (ER) and associates with the accessory molecule class II
invariant chain (Ii) that targets this complex to acidic endosomal
compartments, e.g. LE [24]. Here, Ii is proteolysed until only a small
piece of Ii, known as CLIP, remains bound in the peptide-binding
groove. Upon a conformational change in the MHC II molecule,
mediated by chaperones, CLIP is released facilitating loading of
antigenic peptides [23,24]. Notably, DCs harbour mechanisms that
prevent the rapid acidification of endosomal compartments allowing
endocytosed contents to remain intact for a prolonged time which has
been associated with enhanced ability to present exogenous Ags on
MHC I [25,26].
For presentation of endogenous Ags on MHC I molecules, cytosolic 
proteins are degraded into small peptides by proteasomal proteolysis, 
translocated via TAP transporters into the endoplasmic reticulum (ER) 
for further trimming by aminopeptidases. The optimized peptides are 
subsequently loaded onto newly synthesized MHC I molecules and 
transported toward the Golgi stacks and the plasma membrane. The 
molecular mechanism involved in this exit still remains unknown [27].
The presentation of exogenous Ags on MHC I molecules is termed
cross-presentation. Two main routes have been proposed for this
mechanism: the cytosolic and vacuolar pathway [22,27]. The cytosolic
pathway involves transport of endocytosed Ag into the cytosol for
proteasomal degradation followed by translocation of peptides into ER
via the TAP transporter and thereby into the classical MHC I pathway
[27,28]. Alternatively, several studies have reported that the source of
MHC I molecules in this pathway may be recycled MHC I that gain
access to retro-transported cytosolic Ags in cellular compartments like
the phagosomes and specialized endosomes [27,29,30]. The vacuolar
pathway does not require translocation of Ag from endosomal
compartments to the cytosol, but utilizes acidic lysosomal proteases for
generation of antigenic peptides in the endocytic pathway [27,31,32].
For efficient endosomal peptide/MHC I loading, MHC I molecules
must be delivered into the peptide loading compartment, which is
achieved by constitutively internalization of cell surface MHC class I
molecules [33,34]. A conserved tyrosine residue in the cytosolic tail of
MHC I is required for MHC I endocytosis and its targeting to
lysosomal vesicles in which internalized peptide-MHC I complexes
disassociate in the acidic environment (pH ~ 5) facilitating peptide
exchange [31,35]. Endosomal peptide loading may contribute to rapid
cross-presentation of endocytosed antigenic peptides decreasing the
risk for competition with endogenous peptides present in the ER [22].
Following assembly of peptide-MHC I complexes, these complexes
must be translocated to the cell surface. The exact route by which this
happens remains unknown but it likely depends on the location for
peptide loading. Peptides loaded in the ER are probably transported
via the biosynthetic pathway to the cell surface, whereas endosomal
loading may rely on the endosomal recycling pathway for surface
presentation of peptide-class I complexes [31]. During endocytosis,
membrane proteins and lipids are continuously taken up into
endosomal compartments and to ensure steady surface display, most of
these proteins and lipids must rapidly be returned to the plasma
membrane through endosomal recycling. Studies on inhibition of
endosomal recycling demonstrated impaired cross-presentation of
exogenous Ags, supporting the hypothesis that endosomal recycling
pathways are involved in cross-presentation [35-38].
Regardless of the particular pathways used, the ability of DCs to
cross-present Ags is an important feature for vaccination strategies
aiming at generating potent cellular responses directed against
tumours or pathogens that are inefficiently cleared by the humoral
immune response [39].
Targeting Dendritic Cells
Since the 1990s, the immunotherapeutic potential of DCs has been
explored in clinical settings [39,40]. The idea of harnessing the
potential of DCs to induce immune responses, coupled with the
capacity to generate large numbers of DCs ex vivo, gave rise to ex vivo
antigen-loaded DC-based vaccines [39,40]. Such vaccines consist of ex
vivo generated Ag-loaded autologous DCs that are administered to
patients with the intention of inducing Ag-specific immune responses
[39]. Although these vaccines proved safe, clinical results have been
limited. Furthermore, the production of these cell-based vaccines is
very laborious and expensive [41]. Most likely, one of the major
reasons for the limited clinical effects of vaccination with Ag-loaded
DCs is that the DCs, after being manipulated in vitro, have a poor
immuno-stimulatory potential, when reintroduced into the patient’s
body.
An alternative strategy to the ex vivo-generated DC-based vaccines,
is to directly deliver Ags to specific surface receptors on DCs in vivo. In
this case, manipulation of the cells ex vivo is avoided. Instead, the cells
are targeted in situ, which might benefit from reaching multiple and
rare DC populations in their natural environments. Furthermore, such
vaccines could be standardized off-the-shelf products bringing this
treatment to many more patients than possible with ex vivo method.
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During the past decades many studies have explored the effect of
targeted delivery of Ag to different receptors on DCs and several of
these reported augmented immune responses. Nonetheless, it is still
important to seek to identify new candidate targets that might induce
more effective and longer lasting immune responses. The majority of
studies have only investigated one or few target structures and it is
therefore not known whether targeting the same Ag to another
receptor would elicit markedly different immune responses. In order to
evaluate the relative efficacy of different targets, it is important to study
the effects of targeting these molecules in parallel. Inspired by this, our
group conducted an in vivo targeting study that compared the effect of
targeting to eight different targets; CD11c, CD36, CD205, Clec6A
(Dectin-2), Clec7A (Dectin-1), Clec9A (DNGR-1), Siglec H and PDC-
TREM in the absence of adjuvant [42]. The results demonstrated
enhanced humoral responses upon targeting to six of the selected
targets [42]. As a follow-up, an in vitro screening assay was developed
[43]. In both of these studies, unconjugated rat mAbs directed against
target structures on murine DCs were used as both targeting devices
and Ag. The results demonstrated that this very simple approach can
be useful in screening of candidate targets for Ag-delivery prior to
more complicated studies with relevant targeted Ags. The maturation
stage of the DC is of great importance for the ability to activate
antigen-specific T cells [6,8]. Maturation may be induced by
stimulation of the cell's PRRs. Many of the molecules investigated for
their potential as targets for Ag-delivery are indeed PRRs, so that the
interaction between DCs and the vaccine induce both internalization
and maturation in the targeted cells. Another possibility is to target the
Ag to a suitable endocytic receptor on the DC but then include a PRR
ligand in the vaccine. DCs carry numerous PRRs and it has been
described that the type of PRR targeted influence the character of
immune response initiated by the DC [41,44]. Furthermore, Ag-
delivery to specific subpopulations of DCs may allow for the design of
DC-targeted vaccines that take advantage of the distinct functional
characteristics of the different DC subpopulations [41]. It is therefore
hoped, that DC-targeting vaccines may be created to induce different
types of immune responses appropriate for different clinical situations.
In particular, it is hoped that the DC-targeting approach may lead to
the development of vaccines able to induce effective immune responses
against cancer. Figure 1 illustrates how a DC-targeting anti-cancer
vaccine could function. DC-targeting vaccines may likewise be
designed for induction of potent immune responses against infectious
diseases and possibly also for induction of tolerance as desired in
different autoimmune diseases.
Targeting of antigens to specific receptors
Several strategies have been developed to deliver Ag to DC surface 
receptors. One approach for specific delivery of Ags to DCs is by the 
use of monoclonal antibodies (mAbs). Antibody-based targeting is 
performed either by conjugation of the Ag of choice to a mAb specific 
for selected surface molecules or by genetic engineering in which the 
Ag is fused to a single-chain fragment variable (scFv) specific for the 
target receptor [45-47]. Another approach is ligand-based targeting in 
which Ags are conjugated to pattern recognition receptor ligands, such 
as Toll-like receptor (TLR) ligands (e.g. CpG) and CLR ligands (e.g. 
complex oligosaccharides), or to other ligands, such as the chemokine 
XCL1 [48,49]. A third approach is to use more complex structures, like 
liposomes or viruses, that carry a receptor ligand or receptor-specific 
antibody on their surface and in which the Ag or DNA encoding the 
Ag is incorporated [46,50]. his review
CD205/DEC-205: CD205 is a type I CLR containing 10
carbohydrate recognition domains (CRDs) and a specific triad of
acidic amino acids in its carboxyl terminus [51]. The human and
mouse CD205 are structurally similar, and the only difference is the
number of CRDs of which human CD205 contains 10 CRDs while
mouse CD205 contains 9. Unlike mouse CD205, which is
predominantly expressed on DCs [52], human CD205 is expressed on
several cell types, including DCs, monocytes and B, T and NK cells
[51]. CD205 is an endocytic receptor with a still unknown ligand
specificity [53,54]. CD205 has been described to recognize ligands
expressed during apoptosis and necrosis through a pH-dependent
mechanism indicating a function as a recognition receptor for dying
cells [53,54]. Furthermore, the high-level expression of CD205 on DCs
in the T cell area of lymphoid tissues suggests a function in the
regulation of T cell responses [55,56]. CD205 is internalized by means
of coated pits and vesicles, and recycles through late endosomes or
lysosomes rich in MHC II molecules rather than via early endosomes.
This distinct intracellular trafficking of CD205 is mediated by the
specific acidic amino acids at its cytoplasmic tail [55,57].
Initial studies on targeting of Ag to CD205 using rabbit antibodies
specific for mouse CD205 demonstrated a 100-fold more efficient T
cell response compared to a non-targeting rabbit IgG [55]. Later,
Bonifaz et al. demonstrated that in vivo targeting of ovalbumin (OVA)
to CD205 induced tolerance in the steady state whereas strong
immunity required co-administration of DC maturation signals, like
anti-CD40 or CFA [58]. The necessity for DC maturation was
supported in a study by Corbett et al. in which targeting of CD205 only
triggered antibody responses in the presence of CpG adjuvant [59]. In
addition, two separate groups demonstrated that, in the presence of
adjuvant, targeting of the human immunodeficiency virus (HIV) Gag
p24 to CD205 using a fusion construct induced both high levels of Ag-
specific Th1 responses as well as improved cross-presentation and
priming of Ag-specific CD8+ T cells [60,61]. Interestingly, a recently
published study described potent HIV-specific CD4+ and CD8+ T cell
responses in the GI tract upon nasal delivery of HIV Ags to DCs via
CD205 [62]. Targeting of Ag to CD205 has also been reported by our
group as well as others to induce strong humoral responses, both in the
presence or absence of adjuvant [42,60,62]. Several studies have
explored the effect of targeting tumour-specific Ags to CD205 as a
means of inducing protective and therapeutic immune responses.
Mahnke et al. described that targeting of melanoma Ags (tyrosine-
related protein-2 and gp100) to CD205 in vivo induced potent
melanoma-specific CD4 and CD8 responses in mice when a Toll-like
receptor ligand (CpG) was co-injected. CD205-targeted vaccination
protected the mice against challenge with tumour cells and slowed the
growth of an established B16 melanoma tumour [63]. In addition,
Bonifaz et al. demonstrated that injection of an OVA-linked mAb
specific for CD205 in combination with a DC maturation stimulus
(agonistic anti-CD40) primed naïve CD4+ and CD8+ T cells and
mediated both protective and therapeutic effects towards an OVA-
expressing B16 melanoma [64]. A study by Wang et al. determined the
immunogenicity of a CD205-HER2 (human epidermal growth factor
receptor 2) fusion protein in a mouse breast cancer model and
described that this construct elicited strong CD4+ and CD8+ T cell
responses as well as humoral immunity specific for HER2 Ags. In
addition, CD205-HER2 vaccinated mice were protected from tumour
challenge, a protection mediated by both CD4+ and CD8+ T cells [65].
The first phase 1 clinical trial using a vaccine, CDX-1401, composed of
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a human mAb specific for CD205 fused to the full-length tumour
antigen NY-ESO-1 was published in 2014 (Figure 2). The vaccinefocuses on targeting via mAbs specific for surface structures present on
DCs. proved safe and induced humoral and cellular responses against NY-ESO-1 in patients with tumours that expressed NY-ESO-1 [66].
Figure 1: Principle of DC-targeted vaccination against cancer. 1. An anti-cancer vaccine could be composed of three elements; i) the DC-
targeting element, which can be an antibody or a scFv of an antibody against the target molecule, or it can be a natural ligand for the target
molecule ii) the tumour antigen, and iii) an adjuvant element that initiates activation and maturation of the DCs. 2. Upon interaction with the
targeted DC, the vaccine is internalized and the integrated adjuvant element (e.g. a PRR ligand) conveys a maturation signal to the DC. 3. The
vaccine is degraded and tumour-specific antigenic peptides are transferred both to MHC II and MHC I molecules. The DC migrates to T-cell-
dominated areas of secondary lymphoid tissue while undergoing maturation. 4. The fully mature DC with a high expression of MHC and co-
stimulatory molecules activates antigen-specific T helper cells (Th) and cytotoxic T cells (Tc). Tumour-specific Tc proliferates and
differentiates into active Tc effector cells supported by cytokines secreted by the activated Th1 cells. 5. The Tc effector cells attack the tumour
cells inducing apoptosis in cells exhibiting the cognate peptide/MHC I complexes on their cell membrane.
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Figure 2: CD205-targeting NY-ESO-1 anti-cancer vaccine CDX-1401. The CDX-1401 vaccine (Celldex Therapeutics) is a fusion protein
comprising the tumour Ag NY-ESO-1 in full length fused to a human anti-CD205 antibody. This vaccine was used in the first phase 1 study of
a protein vaccine targeting DCs in vivo in man. A total of 45 patients with advanced malignancies were enrolled. The vaccine was given in
combination with TLR ligands. The figure summarises the results of this phase 1 study [66].
CD209/DC-SIGN: CD209/DC-SIGN (DC-specific ICAM 3-
grabbing non-integrin) is a member of the type II CLRs with a single
CRD displaying specificity for mannose residues [67]. The structure of
the mouse and human homologues of CD209 is very different, but the
expression pattern is similar with both receptors predominantly
expressed on DCs and some macrophages [68,69]. Human CD209 can
interact with several pathogens including viruses, e.g. HIV, human
cytomegalovirus (HCMV) and Ebolavirus, bacteria, e.g
Mycobacterium, and parasites, e.g. Leishmania mexicana [70,71]. In
contrast, studies on mouse CD209 could not demonstrate interaction
with HIV, HCMV, the Ebolavirus glycoprotein or Leishmania
mexicana, which may be due to the structural differences of the two
receptors [68,72]. CD209 has also been reported to be a cell adhesion
receptor that upon binding to ICAM-3 mediates transient interaction
between DCs and resting T cells [69]. Furthermore, CD209 functions
as an Ag receptor that induces endocytosis of soluble ligands into late
endosomal/lysosomal compartments, resulting in processing and
subsequent presentation of antigenic peptides in complex with MHC II
to CD4+ T cells [73]. The dual role of CD209 in adhesion and Ag
uptake provides DCs with a functional receptor that in peripheral
tissues takes up Ag and upon arrival in secondary lymphoid tissues
mediates interaction with T cells [73].
Based on the great functional differences among human and mouse
CD209, mouse CD209 is inadequate as a model for human CD209
explaining the lack of in vivo targeting studies on mouse CD209 [46].
Instead, several targeting studies have been performed using the
human CD209 [73-77]. A study from 2008 compared the efficiency of
in vitro targeting of Ag to DCs using either a humanized antibody
specific for human CD209 or cell-penetrating peptides (CPPs) [75].
CPPs are positively charged peptides that deliver macromolecules such
as proteins, oligo-nucleotides, and plasmid DNA into living cells [78].
The exact mechanism by which CPPs mediate intracellular delivery of
their cargo is still not clear, but it has been demonstrated that CPPs
enter cells via endocytosis [79]. CPPs have been proposed to favour
cross-presentation as they may facilitate uptake and endosomal escape
of conjugated Ags [75]. The study demonstrated that CPPs and anti-
CD209 were equally potent in mediating cross-presentation of
conjugated Ags when targeted to human monocyte-derived DCs in
vitro [75]. Another study by Tacken et al. demonstrated that cross-
linking of a model Ag, keyhole limpet hemocyanin (KLH), to an anti-
human CD209 antibody effectively induced both Ag-specific naïve and
recall T cell responses in vitro [74]. Later on, Tacken et al. evaluated
the effect of targeting CD209 through antibodies specific for the neck
region of the receptor, as previous studies all used antibodies directed
at the CRD of CD209 [76]. They found that anti-neck and anti-CRD
antibodies were differentially internalized. Anti-CRD induced a
clathrin-dependent internalization and mainly channelled Ags into late
endosomal compartments, whereas the uptake of anti-neck was
clathrin-independent and shuttled Ags into early endosomal
compartments rich in MHC I molecules [76]. This study demonstrated
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that intracellular routing of targeted Ags depends on the particular
epitope recognized by the targeting antibodies. In addition, Tacken et
al. investigated the effect of targeting anti-neck/OVA-conjugates to
bone marrow-derived DCs from mice carrying the human CD209
transgene under the promoter of CD11c. The targeted DCs were able
to induce proliferation of both CD4+ (OT-II) and CD8+ (OT-I) OVA-
specific T cells [76]. Later on, a similar setup with anti-CD209
conjugated to OVA induced strong and persistent OT-II and OT-I T
cell responses, which efficiently protected the mice from infection with
an OVA-expressing Listeria monocytogenes [80].
Clec9A/DNGR-1/CD370: Clec9A is a type II CLR with one CRD
and a cytoplasmic immunoreceptor tyrosine-based activation-like
motif [81]. Clec9A has been shown to be expressed by the mouse
CD8α+ subset of cDCs as well as by mouse pDCs [82,83]. Clec9A is
expressed at the cell surface as a glycosylated dimer and can mediate
endocytosis but not phagocytosis [81]. Clec9A is a DAMP recognition
molecule that senses the presence of necrosis and is specialized for the
uptake and processing of dead-cell-associated Ags [11,84]. The dead-
cell ligand for Clec9A has been identified as a filamentous form of
actin complexed with molecules containing the calponin homology-
based actin binding domain (ABD) motif of cytoskeletal molecules
[11].
Several studies have investigated the potential of targeting Ags to
Clec9A in the mouse [82–86]. Targeted delivery of Ags to Clec9A
using mAbs induced a marked enhancement of humoral responses,
even in the absence of adjuvants [83,85,87]. Clec9A was reported to
elicit long-lived, affinity-matured Ab responses with extensive CD4+ T
cell expansion and a high degree of transformation into follicular
helper T cells, which are crucial for antibody production [85,86].
Enhanced CD4 and CD8 T cell proliferative responses was also
reported upon delivery of different Ags (e.g. OVA, MUC1) to Clec9A
either in the presence or absence of adjuvants, which slowed the
tumour growth, mediated eradication of established tumours and/or
prevented tumour implantation [82,83,88]. Notably, our group
observed only weak antibody responses following targeting to Clec9A
in the absence of adjuvants [42] which has also earlier been reported
by Joffre et al. [42,84]. In addition, Joffre et al. showed that in the
absence of adjuvants, targeting of Ag to Clec9A lead to proliferation of
Ag-specific naïve CD4+ T cell that differentiated into Foxp3+
regulatory T cells. In contrast, when anti-Clec9A was administered in
combination with an adjuvant, tolerance was prevented and targeting
promoted development of potent antibody and Th1 or Th17 responses
[84]. A study by Lahoud et al. compared Ag-delivery to three different
receptors predominantly expressed by CD8α+ DCs, namely Clec9A,
CD205 and Clec12A. They found that induction of cytotoxic T cells
required co-administration of adjuvants and were mediated by Ag-
delivery to Clec9A and CD205 but not to Clec12A [85].
Clec7A/Dectin-1/CD369: Clec7A is a type II CLR with a single
CRD and an activating ITAM in its cytoplasmic tail [89]. Clec7A is
atypical compared to other CLRs in that carbohydrate recognition is
Ca2+-ion independent [90]. In the mouse, Clec7A was originally
identified as a DC-specific marker [89], however, later studies
demonstrated that both in mice and humans, Clec7A is expressed on
several other cell types, including macrophages, monocytes and
neutrophils [91,92]. On mouse DCs, the expression of Clec7A has been
reported to be restrained to the CD8α- subset of DCs [93]. Clec7A is a
major receptor for β-glycans with the ability to recognize and
endocytose a number of fungal species including Candida albicans,
Pneumocystis jiroveci and Saccharomyces cerevisiae [94]. Upon
interaction with such organisms in vitro, Clec7A mediates uptake and
killing of live fungal particles through induction of the respiratory
burst and production of protective inflammatory cytokines and
chemokines [94]. Signalling from Clec7A is sufficient for some of these
responses, but induction of respiratory burst and proinflammatory
cytokines requires cooperative signalling from MyD88-coupled TLRs,
like TLR2 and TLR6 [95,96]. Clec7A display other functions beside the
anti-fungal activity and can recognize yet undefined endogenous
ligands on T cells leading to improved proliferation of CD3-activated T
cells suggesting that Clec7A may function as a co-stimulatory
molecule [89]; a function supported by its expression on APCs in the T
cell areas of secondary lymphoid tissues. Furthermore, human Clec7A
can facilitate the uptake of apoptotic cells by DCs mediating cross-
presentation of cellular Ags [97].
Carter et al. investigated the effect of targeting of Ags to Clec7A in
vivo in mice and demonstrated that injection of OVA-anti-Clec7A
conjugates, in combination with poly I:C, induced both CD4+ and
CD8+ T cell responses as well as OVA-specific antibody responses
[93]. A recently published study by our group also reported strong
humoral responses following targeting of Ag to DCs through murine
Clec7A, however, in the absence of adjuvant [42]. Furthermore, a study
using human Clec7A showed that targeted delivery of Ag to human
Clec7A also elicited enhanced CD8+ T cell responses [98].
CD11c: CD11c, also known as αX, forms with the β chain CD18 a
heterodimeric receptor designated complement receptor 4. The
receptor is a member of the family of β2-integrins that also includes
LFA-1 and Mac-1. CD11c/CD18 has been reported to interact with
complement protein (e.g. iC3b and iC3b-opsonized particles), cell
adhesion molecules (e.g. ICAM-1, ICAM-2, and VCAM-1), matrix
proteins (e.g. fibrinogen and collagen) and bacterial cell wall
components (e.g. LPS) [99–101]. The exact function of CD11c is still
not fully elucidated, but CD11c has been described to be involved in
phagocytosis, cell migration, cellular adhesion to endothelium as well
as in cytokine production by monocytes and macrophages [99,101–
103]. The human CD11c/CD18 complex is expressed on several
subsets of DCs but also on macrophages, monocytes, granulocytes,
activated B cells and some T cell populations [101,104]. The mouse
CD11c complex has a more restricted expression pattern and CD11c
are widely used as a DC-specific surface marker [105].
We and others have shown strong antibody responses following Ag-
delivery to CD11c [42,106]. Interestingly, White et al. described that,
apart from the ability to target Ag, anti-CD11c antibodies can deliver a
powerful adjuvant effect even if the Ag was targeted to other molecules
on the DCs [107]. Castro et al. showed that in vivo targeting of Ag to
DCs via CD11c resulted in efficient Ag processing and presentation of
peptides on both MHC I and MHC II molecules inducing robust CD4+
and CD8+ T cell responses [102]. Furthermore, studies using fusion
proteins, consisting of the extracellular domain of human HER2 fused
to the single-chain fragment variable specific for CD11c, have shown
that vaccination with such fusion proteins in mice induced strong
HER2-specific CD4+ and CD8+ T cell responses as well as HER2
antibody responses. Additionally, vaccination protected mice from
subsequent challenge with HER2-positive murine breast tumour cells.
Therapeutic effects were also seen as vaccination elicited rejection of
established HER2-positive tumours [105]. Similar results were
obtained in a study using a DNA vaccine coding for the extracellular
domain of human HER2 fused to the scFv of a mAb specific for
CD11c. In this study, mice immunized with the DNA vaccine in
combination with low-dose cyclophosphamide demonstrated effective
eradication of existing HER2-positive tumours [108].
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Important aspects of targeting antigens to DCs
When using mAbs as Ag targeting devices, the outcome of the
immune response induced by DCs depends on several parameters of
which some are related to the DC subset that is targeted, whereas
others are related to the choice of target receptor or to the particular
mAb used [41]. Regarding the influence of the particular mAb, Tacken
et al. described that the intracellular routing of Ag targeted to CD209
depends on the particular epitope recognized by the targeting mAb
[76]. Similarly, other authors have reported very different outcomes
after targeting Clec9A; some anti-Clec9A mAbs induced strong
humoral responses in the absence of adjuvant, whereas other anti-
Clec9A mAbs were unable to mediate humoral responses in the
absence of adjuvant [42,82,83,85,87]. Similar results have been
published for targeting of Clec7A and CD205 [42]. Differences in
affinity or epitope specificity may explain the very different outcomes
[45]. Another prerequisite for an effective immune response is the
presence of suitable T and B cell epitopes in the Ag or the vaccine. In
support of this, several studies have shown that, when mAbs are used
as both targeting device and as Ag, the isotype of the mAb may affect
the outcome of targeting [83-85], which possibly arise from a lack of
appropriate T cell epitopes in some subclasses, while present in other
subclasses [45]. For instance, cancer vaccines should contain both Th
and Tc epitopes in order to obtain an effective anti-tumour response.
Other important features of targeting are related to the targeted DC
and the targeted receptor. The DC subset presenting the Ag may
determine the type of immune response obtained. Consequently,
targeting specific subsets can be utilized as a means of inducing specific
responses. Thus, in vivo studies have demonstrated that the CD8α+
DCs possess a superior ability to present exogenous Ags on MHC I
molecules [109,44], whereas CD8α- DCs are more efficient at
presenting Ag to CD4+ T cells [59,44,110]. The effect of targeting also
depends on how the different target receptors handle Ags for
presentation. Several studies have shown that different receptors
shuttle Ags into distinct endosomal pathways leading to dissimilar
processing and presentation of the Ag [41,57,44,111]. For instance,
CD206 and CD40 mediate Ag localization to early endosomal
compartments rich in recycling MHC I molecules, which favour cross-
presentation of antigenic peptides, however, the Ag presenting efficacy
is different for the two targets [111,112]. In contrast, targeting of Ag to
CD205 channels Ag directly to late endosomal/lysosomal
compartments, which are rich in MHC II molecules. However, several
studies have reported superior MHC I cross-presentation upon
targeting to CD205 [57,61]. Thus, trafficking to specific endosomal
compartments is not the only determinant of the efficiency of
targeting. Another parameter that has received attention is the speed of
internalization. Initial studies described that slow Ag internalization
was correlated to improved Ag presentation by providing a depot of Ag
that was continuously released over extended periods providing
sustained presentation of peptide-MHC complexes [113]. On the
contrary, a recently published study targeting OVA to different DC
surface receptors described no correlation between the speed of
internalization and Ag presentation on MHC I and MHC II [44].
The route of administration may also affect the outcome of
targeting. The choice of injection site could influence the access to
different subsets of DCs and affect the pattern of DC migration,
ultimately affecting the level of T cell activation induced by vaccination
[12]. A study, in which patients with advanced melanoma were
vaccinated with Ag-loaded DCs, investigated the effect of intradermal
versus intranodal administration and showed superior T cell activation
upon intradermal vaccination [114]. Another study reported that
intradermal delivery of DCs induced stronger effector T cell activation
than intravenous administration [115]. In contrast, a murine in vivo
targeting study investigated the effect of intravenous, intraperitoneal,
or subcutaneous administration and described no significant
differences in the humoral responses elicited by Ag-delivery [42]. It is
very likely that the optimal administration route depends on the type
of vaccine (ex vivo Ag-loaded DC vaccines versus in vivo targeted DC
vaccines), however, the optimal route for such vaccines is still a matter
of debate. Interestingly, a recent study shows that the immunological
balance within the tissue at the injection sites can direct the elicited
immune response either in a stimulatory or a suppressive direction,
why the cytokine micromilieu may be manipulated in order to improve
the effect of Ag-delivery [12].
Conclusion
Antibody-targeted delivery of Ags is a new way of improving the
efficacy of vaccination. So far, a large number of studies in the mouse
have reported potent and improved immune responses upon targeted
delivery of Ags to DC, substantiating the potential of this approach.
However, the translation of these results into a clinical setting is still in
its very beginning. Results from the first clinical trial investigating the
effect of an anti-CD205/NY-ESO-1 fusion protein vaccine given to
melanoma patients have just recently been published [66]. Results
from these and future clinical trials will reveal whether the potential of
DC-targeted vaccines envisioned based on in vivo animal studies will
be fulfilled. It is possible that DC-targeting anti-cancer vaccines could
become a valuable complement to checkpoint blockade therapies [116]
or other forms of immunotherapy. Clinical trials that combine targeted
Ag-delivery with different immune-modulating agents (e.g. flt3 ligand,
anti-IDO1) are already being carried out (clinicaltrials.gov).
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